Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2001, for AVI BioPharma, Inc. (Note: The input metadata listed "Sarepta Therapeutics," but the filing text explicitly identifies the registrant as AVI BioPharma, Inc.). The company is a development-stage biopharmaceutical firm focused on research and development (R&D) with no material product revenues. It has been unprofitable since its inception in July 1980.
Key Financial Metrics
| Metric | Q1 2001 | Q1 2000 |
|---|---|---|
| Revenues | $15,980 | $1,131,873 |
| Operating Expenses | $3,556,746 | $2,372,536 |
| Net Loss | $(3,178,710) | $(1,139,882) |
| Net Loss Per Share | $(0.15) | $(0.07) |
| Cash and Cash Equivalents | $22,001,736 | $9,580,282 |
| Short-term Securities | $4,618,206 | $6,213,586 |
| Total Assets | $30,456,128 | $35,088,393 |
| Accumulated Deficit | $(63,472,543) | $(60,293,833) |
Liquidity: The company holds significant cash reserves ($22.0 million) and short-term securities ($4.6 million). There is no long-term debt reported in the balance sheet.
Material Changes vs. Prior Period
- Revenue Decline: Revenues dropped significantly to $15,980 from $1.13 million in Q1 2000. This decrease is primarily attributed to the receipt of a $1.0 million license fee expansion in Q1 2000, which did not recur in Q1 2001.
- Expense Increase: Operating expenses rose by approximately 50% to $3.56 million. This was driven by increased R&D staffing, outside collaborations, and pre-clinical/clinical testing costs, alongside higher general and administrative expenses for investor relations.
- Net Loss Expansion: The net loss more than doubled to $3.18 million due to the combination of lower revenues and higher operating costs.
- Investment Losses: Short-term securities decreased by $1.6 million due to unrealized losses in market value.
Outlook, Risks, and Management Commentary
- Future Revenue: Management does not expect material revenues from product sales for at least the next 12 months. Future income is expected to come primarily from interest, license fees, and grants.
- Profitability: The company expects to continue incurring losses for the foreseeable future as it expands R&D activities. There is no assurance it will ever achieve profitability.
- Liquidity Outlook: Management believes existing cash resources are sufficient to satisfy cash requirements for the next 24 months.
- Risks: Key risks include the success of R&D and clinical trials, regulatory approvals (FDA), competitive products, and the ability to secure collaborative arrangements.
Investor Verification Checklist
- Company Identity: Verify that the filing pertains to AVI BioPharma, Inc., not Sarepta Therapeutics, as indicated in the metadata request.
- Cash Burn Rate: Confirm the sustainability of the $22 million cash balance against the current quarterly burn rate of approximately $3.9 million (operating + investing cash outflows).
- R&D Pipeline: Review the specific progress of pre-clinical and clinical trials mentioned as the driver for increased expenses.
- Revenue Recurrence: Assess the likelihood of future license fees or grants to offset the absence of the $1 million fee received in the prior year.
- Investment Valuation: Monitor the unrealized losses on short-term securities, which impacted the balance sheet by $1.6 million in this quarter.